- Home
- ACI vs LEGN Comparison
ACI vs LEGN Comparison
Compare ACI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACI | LEGN |
|---|---|---|
| Founded | 1860 | 2014 |
| Country | United States | United States |
| Employees | 270000 | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.9B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACI | LEGN |
|---|---|---|
| Price | $11.03 | $22.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $22.00 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 8.3M | 1.7M |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $83,172,500,000.00 | N/A |
| Revenue This Year | $0.68 | $42.68 |
| Revenue Next Year | $1.47 | $30.52 |
| P/E Ratio | $28.51 | ★ N/A |
| Revenue Growth | ★ 3.46 | N/A |
| 52 Week Low | $11.02 | $16.24 |
| 52 Week High | $20.05 | $43.71 |
Technical Indicators
Market Signals| Indicator | ACI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 21.53 | 32.37 |
| Support Level | N/A | $20.70 |
| Resistance Level | $17.88 | $23.68 |
| Average True Range (ATR) | 0.50 | 1.19 |
| MACD | -0.27 | -0.29 |
| Stochastic Oscillator | 3.90 | 4.81 |
Price Performance
Historical ComparisonAbout ACI Albertsons Companies Inc.
Albertsons Companies Inc is a food and drug retailer in United States. The company operate in well known banners including Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, ACME, Shaw's, Star Market, United Supermarkets, Market Street, Haggen, Kings Food Markets, Balducci's Food Lovers Market, and others.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.